Observation on the efficacy and long-term use of trametinib (Megenin) in patients with lung cancer

Trametinib (Trametinib) is an oral small molecule MEK inhibitor that inhibits RAS-RAF-MEK-ERKMEK1/2 in the signaling pathway blocks tumor cell proliferation and growth signals, thereby inhibiting the spread of cancer cells. In the treatment of lung cancer, this drug is mainly targeted at patients with non-small cell lung cancer (NSCLC) carrying BRAF V600 mutations, especially advanced or metastatic patients. For such patients, trametinib can be used as monotherapy or in combination with a BRAF inhibitor such as dabrafenib to increase efficacy.

Clinical studies have shown that trametinib alone or in combination with BRAF inhibitors can significantly delay disease progression and improve patients' progression-free survival (PFS) and partial survival (OS). In patients with BRAF V600Emutated NSCLC, the objective response rate of combination therapy can reach 60%, while the efficacy of single drug is slightly lower but still significantly better than traditional chemotherapy. Trametinib can inhibit tumor growth and delay the progression of metastasis. It also shows certain efficacy in some patients with brain metastases, improving the overall treatment effect.

During long-term use of trametinib, patients' tolerance and adverse reactions need to be closely observed. Common side effects include rash, diarrhea, edema, fatigue, and mild to moderate cardiac dysfunction. Long-term observation suggests that if patients experience decreased cardiac function or severe skin reactions, they should consider temporarily discontinuing the drug or adjusting the dosage. At the same time, regular follow-up of electrocardiogram, blood pressure, blood routine and liver and kidney function can help early detection and management of potential toxicity.

For patients with lung cancer, the use of trametinib needs to be combined with genetic testing results to ensure that the BRAF mutation is positive before it can be used. During long-term medication, patients should strictly abide by the dosage and medication intervals, cooperate with regular imaging and laboratory examinations, and provide timely feedback on adverse reactions. Physicians can adjust dosage based on efficacy and tolerability to balance therapeutic efficacy and safety. Overall, trametinib provides a precise and effective targeted therapy option for patients with BRAF V600 mutationsNSCLC, which requires scientific management to achieve long-term benefits.

Reference materials:https://www.drugs.com/